-
1
-
-
54849412261
-
-
Canadian Institute for Health Information, Ottawa: Canadian Institute for Health Information
-
Canadian Institute for Health Information. Drug expenditure in Canada 1985-2007. Ottawa: Canadian Institute for Health Information: 2008.
-
(2008)
Drug expenditure in Canada 1985-2007
-
-
-
2
-
-
33745011139
-
Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies
-
CD005979
-
Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2006;(2):CD005979.
-
(2006)
Cochrane Database Syst Rev
, Issue.2
-
-
Aaserud, M.1
Dahlgren, A.T.2
Kösters, J.P.3
Oxman, A.D.4
Ramsay, C.5
Sturm, H.6
-
3
-
-
24944478160
-
What is required to evaluate the impact of pharmaceutical reference pricing?
-
Puig-Junoy J. What is required to evaluate the impact of pharmaceutical reference pricing? Appl Health Econ Health Policy. 2005; 4(2):87-98.
-
(2005)
Appl Health Econ Health Policy
, vol.4
, Issue.2
, pp. 87-98
-
-
Puig-Junoy, J.1
-
4
-
-
34347381507
-
Prescription drug cost sharing: Associations with medication and medical utilization and spending and health
-
Goldman DP, Joyee GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
-
(2007)
JAMA
, vol.298
, Issue.1
, pp. 61-69
-
-
Goldman, D.P.1
Joyee, G.F.2
Zheng, Y.3
-
5
-
-
0038680398
-
Fixed and flexible formularies as cost-control mechanisms
-
Dewa CS, Hoeh JS. Fixed and flexible formularies as cost-control mechanisms. Expert Rev Pharmacoecon Outcomes Res. 2003;3(3):303-315.
-
(2003)
Expert Rev Pharmacoecon Outcomes Res
, vol.3
, Issue.3
, pp. 303-315
-
-
Dewa, C.S.1
Hoeh, J.S.2
-
6
-
-
33847333167
-
Reference drug programs: Effectiveness and policy implications
-
Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy. 2006;81(1):17-28.
-
(2006)
Health Policy
, vol.81
, Issue.1
, pp. 17-28
-
-
Schneeweiss, S.1
-
7
-
-
0037711369
-
Reference pricing for drugs: Is it compatible with U.S. health care?
-
Kanavos P, Reinhardt U. Reference pricing for drugs: is it compatible with U.S. health care? Health Aff (Millwood). 2003;22(3):16-30.
-
(2003)
Health Aff (Millwood)
, vol.22
, Issue.3
, pp. 16-30
-
-
Kanavos, P.1
Reinhardt, U.2
-
8
-
-
1142304152
-
-
Chicago: Kaiser Family Foundation
-
Claxton G, Gabel J, DiJulio B, Whitmore H, Pickreign J, Finder B, et al. Employer health benefits - 2007 annual survey. Chicago: Kaiser Family Foundation: 2007.
-
(2007)
Employer health benefits - 2007 annual survey
-
-
Claxton, G.1
Gabel, J.2
DiJulio, B.3
Whitmore, H.4
Pickreign, J.5
Finder, B.6
-
9
-
-
2342635017
-
-
Ottawa: Cochrane Effective Practice and Organisation of Care Review Group
-
Cochrane EPaOofCRG. Data collection checklist. Ottawa: Cochrane Effective Practice and Organisation of Care Review Group: 2002.
-
(2002)
Data collection checklist
-
-
EPaOofCRG, C.1
-
10
-
-
33745940233
-
The impact of reference pricing of cardiovascular drugs on health care costs and health outcomes: Evidence from British Columbia. Volume 2
-
Technical report. Hamilton: MacMaster University
-
Grootendorst PV, Dolovich LR, Holbrook AM, Levy AR, O-Brien BJ. The impact of reference pricing of cardiovascular drugs on health care costs and health outcomes: evidence from British Columbia. Volume 2: Technical report. Hamilton: MacMaster University: 2002.
-
(2002)
-
-
Grootendorst, P.V.1
Dolovich, L.R.2
Holbrook, A.M.3
Levy, A.R.4
O-Brien, B.J.5
-
11
-
-
0037076037
-
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors
-
Schneeweiss S, Walker AM, Glynn RJ, Madure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346(11):822-829.
-
(2002)
N Engl J Med
, vol.346
, Issue.11
, pp. 822-829
-
-
Schneeweiss, S.1
Walker, A.M.2
Glynn, R.J.3
Madure, M.4
Dormuth, C.5
Soumerai, S.B.6
-
12
-
-
0036207932
-
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
-
Schneeweiss S, Soumerai SB, Glynn RJ, Madure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737-745.
-
(2002)
CMAJ
, vol.166
, Issue.6
, pp. 737-745
-
-
Schneeweiss, S.1
Soumerai, S.B.2
Glynn, R.J.3
Madure, M.4
Dormuth, C.5
Walker, A.M.6
-
13
-
-
0141483571
-
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
-
Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003;74(4):388-400.
-
(2003)
Clin Pharmacol Ther
, vol.74
, Issue.4
, pp. 388-400
-
-
Schneeweiss, S.1
Soumerai, S.B.2
Maclure, M.3
Dormuth, C.4
Walker, A.M.5
Glynn, R.J.6
-
14
-
-
0035653631
-
Effect of a three-tier prescription copay on pharmaceutical and other medical utilization
-
Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-1304.
-
(2001)
Med Care
, vol.39
, Issue.12
, pp. 1293-1304
-
-
Motheral, B.1
Fairman, K.A.2
-
15
-
-
0346041518
-
Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs
-
Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25(12):3147-3161.
-
(2003)
Clin Ther
, vol.25
, Issue.12
, pp. 3147-3161
-
-
Fairman, K.A.1
Motheral, B.R.2
Henderson, R.R.3
-
16
-
-
0344874658
-
The effect of incentive-based formularies on prescription-drug utilization and spending
-
Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
-
(2003)
N Engl J Med
, vol.349
, Issue.23
, pp. 2224-2232
-
-
Huskamp, H.A.1
Deverka, P.A.2
Epstein, A.M.3
Epstein, R.S.4
McGuigan, K.A.5
Frank, R.G.6
-
17
-
-
0642339217
-
Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease
-
Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003;9(2):123-133.
-
(2003)
J Manag Care Pharm
, vol.9
, Issue.2
, pp. 123-133
-
-
Nair, K.V.1
Wolfe, P.2
Valuck, R.J.3
McCollum, M.M.4
Ganther, J.M.5
Lewis, S.J.6
-
18
-
-
28544439412
-
A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures
-
Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry. 2005;42(3):293-310.
-
(2005)
Inquiry
, vol.42
, Issue.3
, pp. 293-310
-
-
Gibson, T.B.1
McLaughlin, C.G.2
Smith, D.G.3
-
19
-
-
27344453213
-
Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
-
Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;11(10):621-628.
-
(2005)
Am J Manag Care
, vol.11
, Issue.10
, pp. 621-628
-
-
Landsman, P.B.1
Yu, W.2
Liu, X.3
Teutsch, S.M.4
Berger, M.L.5
-
20
-
-
34250868997
-
Incentive formularies and changes in prescription drug spending
-
Landon BE, Rosenthal MB, Normand ST, Spettell C, Lessler A, Underwood HR, et al. Incentive formularies and changes in prescription drug spending. Am J Manag Care. 2007;13(6 Pt 2):360-369.
-
(2007)
Am J Manag Care
, vol.13
, Issue.6 PART 2
, pp. 360-369
-
-
Landon, B.E.1
Rosenthal, M.B.2
Normand, S.T.3
Spettell, C.4
Lessler, A.5
Underwood, H.R.6
-
21
-
-
16344364878
-
Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children
-
Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry. 2005;62(4):435-441.
-
(2005)
Arch Gen Psychiatry
, vol.62
, Issue.4
, pp. 435-441
-
-
Huskamp, H.A.1
Deverka, P.A.2
Epstein, A.M.3
Epstein, R.S.4
McGuigan, K.A.5
Muriel, A.C.6
|